Title(s):
Professor of Oncology
Professor of Urology
Professor of Urology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bladder Cancer, Clinical Trials, General Internal Medicine, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology
Education and Experience
Training
- Faculdade De Medicina,Centro De Ciencas (21910 Rio De Janeiro )/ (1972)
Certifications
- Medical Oncology, American Board of Internal Medicine (1979)
- Internal Medicine, American Board of Internal Medicine (1976)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Appointment Phone: 410-955-8964
Location Map
Johns Hopkins Medicine - Green Spring Station
10755 Falls Road
Pavilion I
Lutherville, MD 21093
Appointment Phone: 410-583-2970
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Brady Urological Institute
- Sidney Kimmel Comprehensive Cancer Center
Bio
Expertise
- Bladder Cancer
- Clinical Trials
- General Internal Medicine
- Kidney Cancer
- Medical Oncology
- Prostate Cancer
- Testicular Cancer
- Urological Oncology
Research
Research and Publications
Journal Citations
Armstrong, A.J.; Eisenberger, M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Nature clinical practice. 2006 May;3(5):246-247.
Eisenberger, M.A.; Sinibaldi, V.W. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology (Williston Park). 2006 Jul;20(8):853-862; discussion 863, 867-858.
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Partin, A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol. 2006 Oct;176(4 Pt 1):1404-1408.
Nelson, W.G.; Saad, F.; Debruyne, F.; Eisenberger, M.; Fourcade, R.; Frenkel, E.; Kantoff, P.; Kumon, H.; Nasu, Y.; Oudard, S.; Wirth, M. New Therapeutic Targets and Treatments for Metastatic Prostate Cancer. Prostate Cancer. Paris: Health Publications; 2006.
Sinibaldi, V.J.; Elza-Brown, K.; Schmidt, J.; Eisenberger, M.A.; Rosenbaum, E.; Denmeade, S.R.; Pili, R.; Walczak, J.; Baker, S.D.; Zahurak, M.; Carducci, M.A. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology. 2006 Aug;29(4):395-398.
Antonarakis, E.S.; Blackford, A.L.; Garrett-Mayer, E.; Eisenberger, M.A. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007 Nov 1;25(31):4998-5008.
Armstrong, A.J.; Garrett-Mayer, E.; Ou Yang, Y.C.; Carducci, M.A.; Tannock, I.; de Wit, R.; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-3970.
Armstrong, A.J.; Garrett-Mayer, E.S.; Yang, Y.C.; de Wit, R.; Tannock, I.F.; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 1;13(21):6396-6403.
Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar;69(3):526-531.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Lin, X.; Rogers, C.G.; Mangold, L.A.; Trock, B.; Eisenberger, M.; Partin, A.W.; Nelson, W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-5367.
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Dorey, F.J.; Walsh, P.C.; Partin, A.W. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007 May 1;25(13):1765-1771.
Kantoff, P.W.; Beer, T.M.; D'Amico, A.V.; Dipaola, R.S.; Eisenberger, M.A.; Hussain, M.H.; Kelly, W.K.; Mathew, P.; Morris, M.J.; Ryan, C.J.; Sandler, H.M.; Thompson, I.M.; Carroll, P.R. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep;178(3 Pt 2):S5-8; quiz S4.
Kibel, A.S.; Rosenbaum, E.; Kattan, M.W.; Picus, J.; Dreicer, R.; Klein, E.A.; Chatta, G.S.; Nelson, J.B.; DiPaola, R.S.; Roth, B.J.; Cookson, M.S.; Wilding, G.; Jarrard, D.F.; Beer, T.M.; Ryan, C.W.; Petrylak, D.P.; Benson, M.C.; Partin, A.W.; Garrett-Mayer, E.; Eisenberger, M.A. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-1781.
Mock, V.; Abernethy, A.P.; Atkinson, A.; Barsevick, A.M.; Berger, A.M.; Cella, D.; Cimprich, B.; Cleeland, C.; Eisenberger, M.A.; Escalante, C.P.; Hinds, P.; Jacobsen, P.B.; Kaldor, P.; O'Connor, T.; Otis-Green, S.A.; Piper, B.F.; Pirl, W.F.; Rugo, H.S.; Sabbatini, P.; Stewart, F.M.; Wagner, L.I. Cancer-related fatigue. J Natl Compr Canc Netw. 2007 Nov;5(10):1054-1078.
Sandler, H.M.; Eisenberger, M.A. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007 Sep;178(3 Pt 2):S20-24.
Walsh, P.C.; DeWeese, T.L.; Eisenberger, M.A. Clinical practice. Localized prostate cancer. N Engl J Med. 2007 Dec 27;357(26):2696-2705.
Antonarakis, E.S.; Eisenberger, M.A. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? Nature clinical practice. 2008 Sep;5(9):480-481.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Eisenberger, M.A. The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer. Current Clinical Oncology: Prostate Cancer: Singlaling Networks, Genetics and New Treatment Strategies; 2008. p. 339-354.
Guzzo, T.J.; Rogers, C.G.; Deng, C.Y.; Bivalacqua, T.J.; Palapattu, G.S.; Bastian, P.J.; Eisenberger, M.A.; Schoenberg, M.P.; Gonzalgo, M.L. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int. 2008 Dec;102(11):1539-1543.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Rathkopf, D.; Carducci, M.A.; Morris, M.J.; Slovin, S.F.; Eisenberger, M.A.; Pili, R.; Denmeade, S.R.; Kelsen, M.; Curley, T.; Halter, M.; Collins, C.; Fleisher, M.; Heller, G.; Baker, S.D.; Scher, H.I. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-2965.
Sartor, A.O.; Tangen, C.M.; Hussain, M.H.; Eisenberger, M.A.; Parab, M.; Fontana, J.A.; Chapman, R.A.; Mills, G.M.; Raghavan, D.; Crawford, E.D. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun;112(11):2393-2400.
Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-1159.
Antonarakis, E.S.; Eisenberger, M.A. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nature clinical practice. 2009 Jan;6(1):12-13.
Armstrong, A.J.; Halabi, S.; de Wit, R.; Tannock, I.F.; Eisenberger, M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(1):88-93.
Diaz, L.A., Jr.; Messersmith, W.; Sokoll, L.; Sinibaldi, V.; Moore, S.; Carducci, M.; Eisenberger, M. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009 Oct 21.
Eisenberger, M.A. Treat early or wait? A stubborn question that remains unanswered. Eur Urol. 2009 Jan;55(1):23-25; discussion 26-27.
Eisenberger, M.A. Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71. Eur Urol. 2009 Jan;55(1):248.
Hansel, D.E.; Nakayama, M.; Luo, J.; Abukhdeir, A.M.; Park, B.H.; Bieberich, C.J.; Hicks, J.L.; Eisenberger, M.; Nelson, W.G.; Mostwin, J.L.; De Marzo, A.M. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009 May 1;69(6):603-609.
Keizman, D.; Eisenberger, M.A. LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy? Oncology (Williston Park). 2009 Jun;23(7):631-632.
Lin, J.; Sinibaldi, V.J.; Carducci, M.A.; Denmeade, S.; Song, D.; Deweese, T.; Eisenberger, M.A. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Montie, J.E.; Clark, P.E.; Eisenberger, M.A.; El-Galley, R.; Greenberg, R.E.; Herr, H.W.; Hudes, G.R.; Kuban, D.A.; Kuzel, T.M.; Lange, P.H.; Lele, S.M.; Michalski, J.; Patterson, A.; Pohar, K.S.; Richie, J.P.; Sexton, W.J.; Shipley, W.U.; Small, E.J.; Trump, D.L.; Walther, P.J.; Wilson, T.G. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan;7(1):8-39.
Wang, W.; Tavora, F.; Sharma, R.; Eisenberger, M.; Netto, G.J. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol. 2009 Sep-Oct;27(5):525-528.
Antonarakis, E.S.; Carducci, M.A.; Eisenberger, M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May 1;291(1):1-13.
Antonarakis, E.S.; Chen, Y.; Elsamanoudi, S.I.; Brassell, S.A.; Da Rocha, M.V.; Eisenberger, M.A.; McLeod, D.G. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2010 Nov 23.
Keizman, D.; Eisenberger, M. Is there a role for chemotherapy in nonmetastatic prostate cancer? Curr Opin Support Palliat Care. 2010 Sep;4(3):141-146.
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P.; Verhaak, R.G.; Hoadley, K.A.; Hayes, D.N.; Perou, C.M.; Schmidt, H.K.; Ding, L.; Wilson, R.K.; Van Den Berg, D.; Shen, H.; Bengtsson, H.; Neuvial, P.; Cope, L.M.; Buckley, J.; Herman, J.G.; Baylin, S.B.; Laird, P.W.; Aldape, K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510-522.
Rathkopf, D.; Liu, G.; Carducci, M.A.; Eisenberger, M.A.; Anand, A.; Morris, M.; Slovin, S.F.; Sasaki, Y.; Takahashi, S.; Ozono, S.; Fung, N.K.; Cheng, S.; Gan, J.; Gottardis, M.M.; Obermeier, M.; Reddy, J.; Zhang, S.; Vakkalagadda, B.J.; Wilding, G.; Scher, H.I. Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2010 Dec 3.
Resta, L.P.; Pili, R.; Eisenberger, M.A.; Spitz, A.; King, S.; Porter, J.; Franke, A.; Boinpally, R.; Carducci, M.A.; Sweeney, C.J. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2010 May 6.
Armstrong, A.J.; Eisenberger, M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Nature clinical practice. 2006 May;3(5):246-247.
Eisenberger, M.A.; Sinibaldi, V.W. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology (Williston Park). 2006 Jul;20(8):853-862; discussion 863, 867-858.
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Partin, A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol. 2006 Oct;176(4 Pt 1):1404-1408.
Nelson, W.G.; Saad, F.; Debruyne, F.; Eisenberger, M.; Fourcade, R.; Frenkel, E.; Kantoff, P.; Kumon, H.; Nasu, Y.; Oudard, S.; Wirth, M. New Therapeutic Targets and Treatments for Metastatic Prostate Cancer. Prostate Cancer. Paris: Health Publications; 2006.
Sinibaldi, V.J.; Elza-Brown, K.; Schmidt, J.; Eisenberger, M.A.; Rosenbaum, E.; Denmeade, S.R.; Pili, R.; Walczak, J.; Baker, S.D.; Zahurak, M.; Carducci, M.A. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology. 2006 Aug;29(4):395-398.
Antonarakis, E.S.; Blackford, A.L.; Garrett-Mayer, E.; Eisenberger, M.A. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007 Nov 1;25(31):4998-5008.
Armstrong, A.J.; Garrett-Mayer, E.; Ou Yang, Y.C.; Carducci, M.A.; Tannock, I.; de Wit, R.; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-3970.
Armstrong, A.J.; Garrett-Mayer, E.S.; Yang, Y.C.; de Wit, R.; Tannock, I.F.; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 1;13(21):6396-6403.
Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar;69(3):526-531.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Lin, X.; Rogers, C.G.; Mangold, L.A.; Trock, B.; Eisenberger, M.; Partin, A.W.; Nelson, W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-5367.
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Dorey, F.J.; Walsh, P.C.; Partin, A.W. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007 May 1;25(13):1765-1771.
Kantoff, P.W.; Beer, T.M.; D'Amico, A.V.; Dipaola, R.S.; Eisenberger, M.A.; Hussain, M.H.; Kelly, W.K.; Mathew, P.; Morris, M.J.; Ryan, C.J.; Sandler, H.M.; Thompson, I.M.; Carroll, P.R. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep;178(3 Pt 2):S5-8; quiz S4.
Kibel, A.S.; Rosenbaum, E.; Kattan, M.W.; Picus, J.; Dreicer, R.; Klein, E.A.; Chatta, G.S.; Nelson, J.B.; DiPaola, R.S.; Roth, B.J.; Cookson, M.S.; Wilding, G.; Jarrard, D.F.; Beer, T.M.; Ryan, C.W.; Petrylak, D.P.; Benson, M.C.; Partin, A.W.; Garrett-Mayer, E.; Eisenberger, M.A. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-1781.
Mock, V.; Abernethy, A.P.; Atkinson, A.; Barsevick, A.M.; Berger, A.M.; Cella, D.; Cimprich, B.; Cleeland, C.; Eisenberger, M.A.; Escalante, C.P.; Hinds, P.; Jacobsen, P.B.; Kaldor, P.; O'Connor, T.; Otis-Green, S.A.; Piper, B.F.; Pirl, W.F.; Rugo, H.S.; Sabbatini, P.; Stewart, F.M.; Wagner, L.I. Cancer-related fatigue. J Natl Compr Canc Netw. 2007 Nov;5(10):1054-1078.
Sandler, H.M.; Eisenberger, M.A. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007 Sep;178(3 Pt 2):S20-24.
Walsh, P.C.; DeWeese, T.L.; Eisenberger, M.A. Clinical practice. Localized prostate cancer. N Engl J Med. 2007 Dec 27;357(26):2696-2705.
Antonarakis, E.S.; Eisenberger, M.A. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? Nature clinical practice. 2008 Sep;5(9):480-481.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Eisenberger, M.A. The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer. Current Clinical Oncology: Prostate Cancer: Singlaling Networks, Genetics and New Treatment Strategies; 2008. p. 339-354.
Guzzo, T.J.; Rogers, C.G.; Deng, C.Y.; Bivalacqua, T.J.; Palapattu, G.S.; Bastian, P.J.; Eisenberger, M.A.; Schoenberg, M.P.; Gonzalgo, M.L. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int. 2008 Dec;102(11):1539-1543.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Rathkopf, D.; Carducci, M.A.; Morris, M.J.; Slovin, S.F.; Eisenberger, M.A.; Pili, R.; Denmeade, S.R.; Kelsen, M.; Curley, T.; Halter, M.; Collins, C.; Fleisher, M.; Heller, G.; Baker, S.D.; Scher, H.I. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-2965.
Sartor, A.O.; Tangen, C.M.; Hussain, M.H.; Eisenberger, M.A.; Parab, M.; Fontana, J.A.; Chapman, R.A.; Mills, G.M.; Raghavan, D.; Crawford, E.D. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun;112(11):2393-2400.
Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-1159.
Antonarakis, E.S.; Eisenberger, M.A. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nature clinical practice. 2009 Jan;6(1):12-13.
Armstrong, A.J.; Halabi, S.; de Wit, R.; Tannock, I.F.; Eisenberger, M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(1):88-93.
Diaz, L.A., Jr.; Messersmith, W.; Sokoll, L.; Sinibaldi, V.; Moore, S.; Carducci, M.; Eisenberger, M. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009 Oct 21.
Eisenberger, M.A. Treat early or wait? A stubborn question that remains unanswered. Eur Urol. 2009 Jan;55(1):23-25; discussion 26-27.
Eisenberger, M.A. Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71. Eur Urol. 2009 Jan;55(1):248.
Hansel, D.E.; Nakayama, M.; Luo, J.; Abukhdeir, A.M.; Park, B.H.; Bieberich, C.J.; Hicks, J.L.; Eisenberger, M.; Nelson, W.G.; Mostwin, J.L.; De Marzo, A.M. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009 May 1;69(6):603-609.
Keizman, D.; Eisenberger, M.A. LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy? Oncology (Williston Park). 2009 Jun;23(7):631-632.
Lin, J.; Sinibaldi, V.J.; Carducci, M.A.; Denmeade, S.; Song, D.; Deweese, T.; Eisenberger, M.A. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Montie, J.E.; Clark, P.E.; Eisenberger, M.A.; El-Galley, R.; Greenberg, R.E.; Herr, H.W.; Hudes, G.R.; Kuban, D.A.; Kuzel, T.M.; Lange, P.H.; Lele, S.M.; Michalski, J.; Patterson, A.; Pohar, K.S.; Richie, J.P.; Sexton, W.J.; Shipley, W.U.; Small, E.J.; Trump, D.L.; Walther, P.J.; Wilson, T.G. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan;7(1):8-39.
Wang, W.; Tavora, F.; Sharma, R.; Eisenberger, M.; Netto, G.J. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol. 2009 Sep-Oct;27(5):525-528.
Antonarakis, E.S.; Carducci, M.A.; Eisenberger, M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May 1;291(1):1-13.
Antonarakis, E.S.; Chen, Y.; Elsamanoudi, S.I.; Brassell, S.A.; Da Rocha, M.V.; Eisenberger, M.A.; McLeod, D.G. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2010 Nov 23.
Keizman, D.; Eisenberger, M. Is there a role for chemotherapy in nonmetastatic prostate cancer? Curr Opin Support Palliat Care. 2010 Sep;4(3):141-146.
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P.; Verhaak, R.G.; Hoadley, K.A.; Hayes, D.N.; Perou, C.M.; Schmidt, H.K.; Ding, L.; Wilson, R.K.; Van Den Berg, D.; Shen, H.; Bengtsson, H.; Neuvial, P.; Cope, L.M.; Buckley, J.; Herman, J.G.; Baylin, S.B.; Laird, P.W.; Aldape, K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510-522.
Rathkopf, D.; Liu, G.; Carducci, M.A.; Eisenberger, M.A.; Anand, A.; Morris, M.; Slovin, S.F.; Sasaki, Y.; Takahashi, S.; Ozono, S.; Fung, N.K.; Cheng, S.; Gan, J.; Gottardis, M.M.; Obermeier, M.; Reddy, J.; Zhang, S.; Vakkalagadda, B.J.; Wilding, G.; Scher, H.I. Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2010 Dec 3.
Resta, L.P.; Pili, R.; Eisenberger, M.A.; Spitz, A.; King, S.; Porter, J.; Franke, A.; Boinpally, R.; Carducci, M.A.; Sweeney, C.J. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2010 May 6.
Research Interests
- Prostate Cancer
More Info
Languages
- English
- German
- Portuguese
- Spanish
Clinical Trials
- prostate cancer
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts